Solventum Corp (SOLV) stock
SOLVNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3092% above fair value
$88.81+0.19 (+0.21%)
Close on Nov 12, 2026Market cap $15.12BP/E 99.8Yield –
Solventum ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Solventum's ebitda for the twelve months ending Sep 30, 2026 was $975.00M, down 64.1% year over year. For fiscal 2025 it was $2.67B, up 67.8% from the year before.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.67B | +67.8% |
| FY2024 | Dec 31, 2024 | $1.59B | -29.4% |
| FY2023 | Dec 31, 2023 | $2.25B | -0.8% |
| FY2022 | Dec 31, 2022 | $2.27B | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $204.00M | -88.7% |
| Q2 FY2026 | Jun 30, 2026 | $314.00M | -6.5% |
| Q1 FY2026 | Mar 31, 2026 | $216.00M | -23.1% |
| Q4 FY2025 | Dec 31, 2025 | $241.00M | -15.7% |
| Q3 FY2025 | Sep 30, 2025 | $1.81B | +343.9% |
| Q2 FY2025 | Jun 30, 2025 | $336.00M | -10.9% |
| Q1 FY2025 | Mar 31, 2025 | $281.00M | -46.0% |
| Q4 FY2024 | Dec 31, 2024 | $286.00M | -47.5% |
| Q3 FY2024 | Sep 30, 2024 | $408.00M | -37.0% |
| Q2 FY2024 | Jun 30, 2024 | $377.00M | -31.5% |
| Q1 FY2024 | Mar 31, 2024 | $520.00M | +2.0% |
| Q4 FY2023 | Dec 31, 2023 | $545.00M | – |
| Q3 FY2023 | Sep 30, 2023 | $648.00M | – |
| Q2 FY2023 | Jun 30, 2023 | $550.00M | – |
| Q1 FY2023 | Mar 31, 2023 | $510.00M | – |
See a number that looks wrong?